Health and Healthcare
Top Biotech Earnings Reports to Watch This Week
Published:
Last Updated:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week. While health care doesn’t seem to be anywhere near the topic of debate ahead of this election season, it has the potential to be hugely affected by whatever party takes power in the United States.
For the other notable earnings this week, check out the Dow Jones industrials earnings and other major earnings previews.
Note that the earnings and revenue estimates may change ahead of the formal reports, and some companies may reschedule reporting dates as well.
Biogen Inc. (NASDAQ: BIIB) is set to report its most recent results on Tuesday. The consensus estimates from Thomson Reuters call for earnings per share (EPS) of $6.78 and $3.33 billion in revenue. Shares were changing hands at $320.41 on Friday’s close. The 52-week range is $249.17 to $388.67.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to report its third-quarter results on Wednesday. The consensus estimates are $1.74 in EPS and $1.02 billion in revenue. Shares traded at $125.89 as last week came to a close. The consensus price target is $163.41, and the 52-week trading range is $102.10 to $142.24.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is set to share its latest quarterly earnings on Thursday. The consensus estimates call for a net loss of $0.21 per share on $366.93 million in revenue. Shares were at $103.22 on Friday’s close, in a 52-week range of $75.81 to $106.74. The consensus price target is $120.05.
Bristol-Myers Squibb Co. (NYSE: BMY) is expected to reveal its third-quarter results on Thursday. The consensus forecast calls for $0.91 in EPS, as well as $5.72 billion in revenue. The stock ended last week at $54.30 per share. The consensus price target is $61.59, and the 52-week range is $49.96 to $70.05.
Celgene Corp. (NASDAQ: CELG) also will share its latest quarterly earnings on Thursday. The consensus estimates call for $2.34 in EPS and $1.74 billion in revenue. Shares were at $99.62 as Friday’s trading ended, in a 52-week range of $95.45 to $119.29. The consensus price target is $128.22.
And Gilead Sciences Inc. (NASDAQ: GILD) is expected to reveal its third-quarter results on Thursday as well. The consensus forecast calls for $1.63 in EPS, as well as $5.37 billion in revenue. The stock ended last week at $73.27 per share. The consensus price target is $87.91, and the 52-week trading range is $64.27 to $89.54.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
